Rakez K Kayed

US Patent:

20070110750, May 17, 2007

Filed:

Sep 13, 2004

Appl. No.:

10/572001

Inventors:

Charles Glabe - Irvine CA, US
Rakez Kayed - Irvine CA, US

Assignee:

The Regents of the University of California - Oakland CA

International Classification:

A61K 39/395
G01N 33/567
C07K 16/40
G01N 33/53

US Classification:

424146100, 530388260, 424178100, 435007200, 977906000

Abstract:

Methods for the production of monoclonal antibodies specific to conformational epitope(s) of a prefibrilar aggregate(s) which contribute to amyloid fibril formation in human or animal subjects who suffer from amyloid diseases (e.g. Alzheimer's Disease) and the hybridomas and monoclonal antibodies produced therefrom. Also, the use of such monoclonal antibodies in the immunization of human or animal subjects against Alzheimer's Disease or other amyloid diseases and/or for the diagnosis or detection of Alzheimer's Disease or other amyloid diseases. The monoclonal antibodies may be administered concomitantly or in combination with anti-inflammatory agents, such as gold or gold containing compounds, to decrease neural inflammation associated with amyloid diseases (e.g. Alzheimer's Disease).

US Patent:

20100316590, Dec 16, 2010

Filed:

Jun 14, 2010

Appl. No.:

12/814953

Inventors:

Rakez Kayed - Galveston TX, US

Assignee:

THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM - Austin TX

International Classification:

A61K 31/765
C12N 5/071
A61P 25/28

US Classification:

424 7837, 435325

Abstract:

Embodiments of the invention include the treatment of amyloid oligomer toxicity by administering a membrane sealant co-polymer, for example poloxamer 188 (P188).

US Patent:

20110200609, Aug 18, 2011

Filed:

Jul 27, 2009

Appl. No.:

13/055908

Inventors:

Charles G. Glabe - Irvine CA, US
Rakez Kayed - Irvine CA, US

Assignee:

THE REGENTS OF THE UNIVERSITY OF CALIFORNIA - Oakland CA

International Classification:

A61K 39/395
G01N 33/566
C07K 16/18
A61P 25/28
A61P 29/00
A61P 25/00

US Classification:

4241521, 436501, 5303882, 435 71

Abstract:

Monoclonal antibody compositions, methods of production and use. The monoclonal antibodies are specific to conformational epitope(s) of a prefibrillar aggregate(s) which contribute to amyloid fibril formation in human or animal subjects who suffer from amyloid diseases (e.g., Alzheimer's Disease) and the hybridomas and monoclonal antibodies produced therefrom. The monoclonal antibodies are useable for immunization of human or animal subjects against Alzheimer's Disease or other amyloid diseases and/or for the diagnosis or detection of Alzheimer's Disease or other amyloid diseases. The monoclonal antibodies may be administered concomitantly or in combination with anti-inflammatory agents, such as gold or gold containing compounds, to decrease neural inflammation associated with amyloid diseases (e.g., Alzheimer's Disease).

US Patent:

20120148591, Jun 14, 2012

Filed:

Oct 14, 2011

Appl. No.:

13/273507

Inventors:

Rakez Kayed - Galveston TX, US

Assignee:

The Board of Regents of The University of Texas System - Austin TX

International Classification:

A61K 39/395
G01N 33/566
A61P 25/28
C07K 16/18
C07K 14/00

US Classification:

4241391, 5303879, 5303873, 530324, 435 792, 436501

Abstract:

Embodiments of the invention are directed to compositions and methods related to immunogenic compositions comprising the amino acid sequence of SEQ ID NO:1 and amyloid oligomer specific antibodies that specifically bind an oligomer comprising such a peptide.

US Patent:

20130028914, Jan 31, 2013

Filed:

Aug 30, 2010

Appl. No.:

13/393220

Inventors:

Rakez Kayed - Galveston TX, US

Assignee:

The Board of Regents of the University of Texas System - Austin TX

International Classification:

C07K 16/18
C07K 16/46
A61P 25/00
A61K 39/00
A61K 39/395
G01N 33/566
C07K 14/435

US Classification:

4241721, 436501, 435 71, 435 792, 435 794, 5303882, 5303873, 53038815, 530352, 4241841

Abstract:

Embodiments of the invention are directed to compositions and methods related to Tau oligomers and Tau oligomer specific antibodies.

US Patent:

20060280733, Dec 14, 2006

Filed:

Sep 12, 2003

Appl. No.:

10/527678

Inventors:

Rakez Kayed - Irvine CA, US
Charles Glabe - Irvine CA, US

Assignee:

The Regents of the University of California - Oakland CA

International Classification:

A61K 39/395
A61K 39/00
G01N 33/53
G01N 33/567
C12P 21/04

US Classification:

424133100, 424185100, 514012000, 435070210, 435007200

Abstract:

Compositions of matter that comprise one or more conformational epitopes found on amyloid peptide aggregates, antibodies to such epitopes and methods for making and using the compositions, eptitopes and/or antibodies. The invention includes synthetic or isolated compositions that contain or consist of certain conformational epitopes that are found on peptide aggregates (e.g., toxic peptide aggregates) present in human or veterinary patients who suffer from, or who are likely to develop, amyloid diseases (e.g., Alzheimer's Disease). The invention includes methods for the detection, treatment and prevention of diseases in humans or animals, using such compositions. The invention further includes antibodies which bind to the conformational epitopes as well as methods for making such antibodies and methods for the detection, treatment and prevention of diseases and/or identification of potential therapies (e.g., drug screening) using such antibodies.

US Patent:

20170096476, Apr 6, 2017

Filed:

Oct 3, 2016

Appl. No.:

15/283779

Inventors:

Rakez Kayed - Galveston TX, US

Assignee:

The Board of Regents of the University of Texas System - Austin TX

International Classification:

C07K 16/18
G01N 33/53
C07K 14/47

Abstract:

Embodiments are directed to compositions comprising a conformation-dependent antibody that specifically binds oligomeric Aβ-42, and the methods of using the same.

US Patent:

20150322143, Nov 12, 2015

Filed:

Jul 28, 2015

Appl. No.:

14/810760

Inventors:

Rakez KAYED - Galveston TX, US

Assignee:

THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM - Austin TX

International Classification:

C07K 16/18
G01N 33/68

Abstract:

Embodiments of the invention are directed to compositions and methods related to immunogenic compositions comprising the amino acid sequence of SEQ ID NO:1 and amyloid oligomer specific antibodies that specifically bind an oligomer comprising such a peptide.